Methotrexate [BSA]

Name: Methotrexate [BSA]
SKU: DAGA-351B
Rating: 5 (1 reviews)

Methotrexate BSA Conjugated, Synthetic antigen for LFIA

COA

SDS

Datasheet

Summary

Nature

Synthetic

Tag/Conjugate

BSA

Alternative Names

L-(+)-AMETHOPTERIN; Methotrexate; MTX; ANTIFOLAN; NSC 740; 4-AMINO-N 10-METHYLPTEROYL-L-GLUTAMIC ACID; 4-AMINO-10-METHYLPTEROYLGLUTAMIC ACID; NCI-C04671;

Format

Liquid

Concentration

Batch dependent - please inquire should you have specific requirements.

Buffer

PBS buffer

Preservative

None

Storage

Store at -20°C. Avoid repeated freeze/thaw cycles

Antigen Description

Methotrexate is in the class of medications called antimetabolites. The drug is used to treat severe psoriasis, rheumatoid arthritis and certain types of cancer. It works by slowing the proliferation of cells. Specifically, it inhibits the enzyme dihydrofolate reductase that is necessary for the synthesis of folic acid, which is required for the synthesis of DNA, RNA, thymidylates and proteins.

Keywords

L-(+)-AMETHOPTERIN; Methotrexate; MTX; ANTIFOLAN; NSC 740; 4-AMINO-N 10-METHYLPTEROYL-L-GLUTAMIC ACID; 4-AMINO-10-METHYLPTEROYLGLUTAMIC ACID; NCI-C04671;

Citations

Have you cited DAGA-351B in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

Small Molecule Drug Monitoring

QA & Reviews

Customer Reviews

References

Use of haemostatic gel in the management of cervical pregnancy: a case report

EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE

Authors: Han, Ji Yeon; Kim, Hoon; Kim, Sung Woo; Ku, Seung-Yup; Suh, Chang Suk; Kim, Seok Hyun

Abstract

Purpose This case report aimed to describe haemostatic agents with systemic methotrexate (MTX) as an effective management for cervical pregnancy with bleeding. Case presentation A 34-year-old nulligravida patient was referred due to vaginal spotting and lower abdominal discomfort, and was diagnosed with a cervical pregnancy at 6 weeks of gestation. The patient was treated with a multi-dose MTX regimen, and the bleeding was successfully controlled with haemostatic agents, which were applied at the bleeding site of the cervix. After completion of MTX treatment, beta human chorionic gonadotropin (beta-hCG) decreased to undetectable range. Furthermore, patients could preserve her uterus and maintain fertility. Conclusion Haemostatic agents can be regarded as an effective option for vaginal bleeding due to cervical pregnancy.

Efficacy of oral methotrexate (MTX) monotherapy vs oral MTX plus narrowband ultraviolet light B phototherapy in palmoplantar psoriasis

DERMATOLOGIC THERAPY

Authors: Ara, Shamim; Mowla, Mohammad Rafiqul; Alam, Mansurul; Khan, Ismail

Abstract

Palmoplantar psoriasis (PPP) is a chronic, inflammatory dermatosis of the palms and/or soles with significant morbidity. It is notoriously difficult to treat and unresponsive to traditional topical agents. We aim to compare the effect of oral methotrexate (MTX) monotherapy vs MTX plus narrowband ultraviolet light B (NB-UVB) in the treatment of recalcitrant PPP. This was a comparative clinical trial involving 90 patients of PPP. Eligible patients were randomly assigned to one of the two treatment groups. We aim patients in group A received 10 mg oral MTX weekly, and patients in group B received oral MTX 10 mg weekly and NB-UVB sessions twice weekly for 12 weeks. There was a statistically significant difference in reduction of modified PPP Area Severity Index (m-PPPASI) of patients in MTX plus NB-UVB at week 12. The mean m-PPPASI at week 12 was 3.66 +/- 2.11 in MTX plus NB-UVB group and 6.51 +/- 2.04 in MTX only group (P < .001). Marked improvement (m-PPPASI 75) was achieved in 20 (44.44%) patients in MTX plus NB-UVB group compared with 6 (13.3%) in MTX monotherapy group (P < .001). Combination of MTX and NB-UVB phototherapy helps to attain a better clinical response (reduction in m-PPPASI score) than MTX monotherapy in the treatment of recalcitrant PPP.